CN103156879A - 血中酒精浓度上升抑制剂及血液酒精浓度上升抑制方法 - Google Patents
血中酒精浓度上升抑制剂及血液酒精浓度上升抑制方法 Download PDFInfo
- Publication number
- CN103156879A CN103156879A CN2012105395963A CN201210539596A CN103156879A CN 103156879 A CN103156879 A CN 103156879A CN 2012105395963 A CN2012105395963 A CN 2012105395963A CN 201210539596 A CN201210539596 A CN 201210539596A CN 103156879 A CN103156879 A CN 103156879A
- Authority
- CN
- China
- Prior art keywords
- dextrin
- alcohol concentration
- blood
- blood alcohol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title abstract description 25
- 210000004369 blood Anatomy 0.000 title abstract description 25
- 229920001353 Dextrin Polymers 0.000 claims abstract description 74
- 239000004375 Dextrin Substances 0.000 claims abstract description 74
- 235000019425 dextrin Nutrition 0.000 claims abstract description 74
- 230000000630 rising effect Effects 0.000 claims description 22
- 235000019621 digestibility Nutrition 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 7
- 230000035622 drinking Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000027700 hepatic dysfunction Diseases 0.000 abstract 1
- 230000035987 intoxication Effects 0.000 abstract 1
- 231100000566 intoxication Toxicity 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000008213 purified water Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 235000013334 alcoholic beverage Nutrition 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 108090000637 alpha-Amylases Proteins 0.000 description 9
- 102000004139 alpha-Amylases Human genes 0.000 description 9
- 229940024171 alpha-amylase Drugs 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000006408 oxalic acid Nutrition 0.000 description 6
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003625 amylolytic effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- VKJLHZZPVLQJKG-JAGYOTNFSA-N (3r,4r,4ar,5r,6ar,6as,6br,8ar,9s,10s,12ar,14bs)-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,4,5,10-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@H](O)[C@]3(CO)[C@H](O)C[C@]21C VKJLHZZPVLQJKG-JAGYOTNFSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 2
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VKJLHZZPVLQJKG-UHFFFAOYSA-N Theasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(CO)C(O)CC21C VKJLHZZPVLQJKG-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 2
- 229940005991 chloric acid Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003863 metallic catalyst Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 2
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 2
- 229960000903 pantethine Drugs 0.000 description 2
- 235000008975 pantethine Nutrition 0.000 description 2
- 239000011581 pantethine Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000015041 whisky Nutrition 0.000 description 2
- VGTALXLMFZXQSK-SORNOFNASA-N (2s,3r,4s,6ar,6br,8as,12as,14br)-2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)C2CC[C@@]3(C)[C@]4(CO)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CCC3[C@]21C VGTALXLMFZXQSK-SORNOFNASA-N 0.000 description 1
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- VGTALXLMFZXQSK-UHFFFAOYSA-N Presenegenin Natural products C1C(O)C(O)C(C)(C(O)=O)C2CCC3(C)C4(CO)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C VGTALXLMFZXQSK-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- FKKZBCYPCGDQKZ-UHFFFAOYSA-N tenuifolin Natural products CC1(C)CCC2(CCC3(O)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(C)(C5CCC34C)C(=O)O)C2C1)C(=O)O FKKZBCYPCGDQKZ-UHFFFAOYSA-N 0.000 description 1
- 108010075550 termamyl Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种血中酒精浓度上升抑制剂及血液酒精浓度上升抑制方法。本发明提供一种可以预防饮酒时的酩酊状态,还可以预防由饮酒导致的脂肪肝等肝功能损伤的血中酒精浓度上升抑制剂,及使用所述抑制剂的血中酒精浓度抑制方法。本发明的血中酒精浓度上升抑制剂以糊精类作为有效成分,本发明的血中酒精浓度上升抑制方法的特征在于:在摄取酒精时,相对于摄取1质量份酒精,而摄取0.5质量份以上的消化性糊精和/或难消化性糊精。
Description
技术领域
本发明涉及一种抑制摄取酒精饮料时血中酒精浓度急剧上升的抑制剂及抑制方法。
背景技术
在过度地摄取酒精的情况下,常常可见呈现急性及慢性的中毒症状的情况,因此先前为了预防酩酊、促进醒酒、预防酒精中毒而进行了各种研究来寻找特效药。尤其是关于预防酩酊、促进醒酒,提出有包括自古以来的传言的各种物质。
例如先前提出了水果中大量含有的果糖及葡萄糖、柿子萃取物、有机酸、乙酸钠、酵母菌体、ω6系不饱和脂肪酸、氯化肉碱(carnitine chloride)及竹节人参、刺五加等作为酩酊预防剂或醉后不适防止剂。
另外,例如专利文献1中揭示了一种酒精吸收抑制组合物,其特征在于:其是含有由酿造日本酒而获得的酒糟的干燥物而成。专利文献2中揭示了一种酒精吸收抑制剂,其是以咖啡因作为有效成分。专利文献3中揭示了一种酒精吸收抑制剂,其特征在于:含有以齐墩果酸(oleanolic acid)作为皂苷元(sapogenin)的糖苷、以远志皂苷元(presenegenin)作为皂苷元的糖苷、以常春藤皂苷元(hederagenin)作为皂苷元的糖苷及以原七叶皂苷元(protoescigenin)为皂苷元的糖苷中的至少一种。专利文献4中揭示了一种血中酒精浓度上升阻碍饮料,其特征在于:其含有甘油作为血中酒精浓度上升阻碍用有效成分。专利文献5中揭示了一种血中酒精浓度上升抑制用组合物,其含有碱性氨基酸或其盐作为有效成分。专利文献6中揭示了一种血中的酒精代谢改善组合物,其是以将大豆蛋白酶解而获得的平均分子量为500~15000的肽混合物作为有效成分。专利文献7中揭示了一种酒精吸收代谢调整剂,其是以大豆加工物作为有效成分。专利文献8中揭示了一种用来降低血中酒精浓度的饮食用组合物,其含有以红糖为原料发酵而成的发酵产物。
然而,所述现有技术的效果不充分,且其饮料的投予存在困难等,达到实用化的较少。
[现有技术文献]
[专利文献]
[专利文献1]日本专利特开平11-228428号公报
[专利文献2]日本专利特开平08-277221号公报
[专利文献3]日本专利特开平07-053385号公报
[专利文献4]日本专利特开平06-014751号公报
[专利文献5]日本专利再表2007-023931号公报
[专利文献6]日本专利再表2006-106704号公报
[专利文献7]日本专利特开2001-226277号公报
[专利文献8]日本专利特开2010-115124号公报
发明内容
[发明所欲解决的课题]
本发明提供一种更安全且更容易投予的抑制饮酒时血中酒精浓度上升的物质。本发明意在提供一种可以防止饮酒时的酩酊状态,还可以预防由饮酒导致的脂肪肝等肝功能损伤的血中酒精浓度上升抑制剂及其使用方法。
[解决课题的技术手段]
本发明人等人对防止饮酒时的酩酊的食品原材料反复进行了努力研究,结果发现糊精类、尤其是难消化性糊精显着地抑制饮酒后的血中酒精浓度,并进一步反复研究,从而完成本发明。即,本发明涉及一种血中酒精浓度上升抑制剂,其特征在于:其含有糊精类、尤其是消化性糊精或者难消化性糊精作为有效成分。另外,本发明提供一种血中酒精浓度上升抑制方法,其是在摄取酒精饮料时摄取酒精摄取量的1/2以上的糊精类。
[发明的效果]
根据本发明,可以提供一种能抑制摄取酒精饮料后血中酒精浓度急剧上升、安全且容易投予的血中酒精浓度上升抑制剂及血中酒精浓度上升抑制方法。利用所述抑制剂及抑制方法,可以防止饮酒时的酩酊状态,并且中长期来看还可以预防脂肪肝等由饮酒导致的肝损伤,而实现健康的饮酒。
附图说明
图1表示对大鼠(rat)投予纯化水(H2O)、40%糊精(TK-16)溶液或者40%难消化性糊精(FS2)溶液和等量的40%乙醇水溶液后的血中乙醇浓度的演变。*表示相对于纯化水有显着差异。
图2表示对大鼠投予纯化水(H2O)、20%难消化性糊精(FS2)溶液或者40%难消化性糊精(FS2)溶液和等量的40%乙醇水溶液后的血中乙醇浓度的演变。*表示相对于纯化水有显着差异。
具体实施方式
在本说明书中,所谓“糊精类”,是利用酸或者淀粉酶(amylase)等淀粉分解酶将淀粉或者焙烧糊精分解而获得的淀粉分解物、焙烧糊精分解物或者淀粉分解物、焙烧糊精分解物的衍生物的统称。“糊精类”包括焙烧糊精、消化性糊精、难消化性糊精及这些的氢化物。
所谓消化性糊精,是利用酸或者淀粉酶等淀粉分解酶将淀粉分解而获得的淀粉分解物。所谓难消化性糊精,是利用酸或者淀粉酶等淀粉分解酶将焙烧糊精分解而获得的非消化性糊精。所谓消化性糊精或难消化性糊精的氢化物,是指在金属催化剂的存在下,且在加压条件下,使消化性糊精或难消化性糊精接触氢气而进行接触还原的产物。
为了制造糊精类而使用的焙烧糊精是在盐酸等无机酸或者草酸等有机酸的存在下将淀粉加热到120~200℃而获得的干式淀粉分解物,是含有少量非消化性成分的糊精。
更详细而言,焙烧糊精是通过如下方式获得:于淀粉中添加矿酸(例如盐酸、硝酸、硫酸)、优选盐酸,例如相对于100质量份的淀粉以1质量%的盐酸水溶液的形式添加3~10质量%,并进行加热处理。优选在加热处理之前,为了使淀粉与矿酸的水溶液均匀地混合,而在适当的混合机中搅拌、熟化(数小时),此后优选以100~120℃左右进行预干燥,而使混合物中的水分减少到5质量%左右。加热处理时,适当的是以120~200℃、优选150~200℃进行10~120分钟、优选30分钟~120分钟。加热处理的温度提高时目标产物中的难消化性成分的含量增加,并且存在自180℃起生成着色物质的倾向,因此更优选150~180℃。
在消化性糊精或非消化性糊精的制造中,淀粉或者焙烧糊精的利用酸的分解中所使用的酸可以是有机酸(例如草酸、柠檬酸),也可以是无机酸(例如盐酸、硝酸、硫酸),但优选盐酸、草酸等,更优选盐酸。
消化性糊精的制造中,一般使用湿式分解。更详细的制造方法如下。以浓度成为20~40%的方式使淀粉悬浮于水中,并利用碳酸钙或草酸将pH值调整为5.5~6.5,其后相对于固形物成分而添加0.05~0.3质量%的α-淀粉酶,再于加热温度80~100℃下水解30~60分钟左右而使淀粉液化,接着加压至0.2MPa左右,或者添加草酸等酸而使酶反应停止。将反应停止液精制、浓缩、干燥而制成制品。
难消化性糊精的更详细的制造方法如下。将焙烧糊精制成20~45质量%左右的水溶液,并将焙烧糊精水溶液的pH值调整成5.5~6.5,再对焙烧糊精添加α-淀粉酶,例如为拖麦米尔(Termamyl)60L(商品名,诺和诺德生物工程(Novo Nordisk Bioindustry)公司制造)时,相对于焙烧糊精而添加0.05~0.2质量%。当使用其他α-淀粉酶时,根据该酶的效价添加同等的量即可。添加α-淀粉酶后加热溶液,在α-淀粉酶的作用温度即85~100℃(根据α-淀粉酶的种类而有所不同)下水解30分钟~2小时。接着,使温度上升到120℃左右(α-淀粉酶的失活温度)而停止α-淀粉酶作用。此时,也可以添加盐酸或草酸等酸使pH值降低至α-淀粉酶失活的程度、即至pH值4左右。
所述消化性糊精或难消化性糊精也可以在雷氏镍等金属催化剂的存在下,且在80~120kg/cm2、120~140℃的条件下,使之接触氢气而进行接触还原而使用。
作为这些糊精类,例如可以列举:市售的TK-16、Pinedex#1、Pinedex#2、Fibersol 2、Fibersol 2H(以上为松谷化学工业股份有限公司制造)及朗纤优(Nutriose)(罗盖特(Roquette)公司制造)。
另外,本发明中的糊精类也可以是具有类似于糊精的结构及功能的合成糊精衍生物,例如丹尼斯克日本(Danisco Japan)股份有限公司销售的聚糊精(polydextrose)。
在本说明书中,所谓“糊精衍生物”,是将糊精通过化学方法和/或酶加工而成的产物,除了所述聚糊精,还包括例如:使糖基转移酶作用于糊精而获得的支链糊精,使环糊精生成酶作用于淀粉而获得的环糊精。
本发明的血中酒精浓度上升抑制剂及抑制方法中使用的代表性糊精类为消化性糊精或者难消化性糊精,但从效果的观点来看,更优选难消化性糊精。也可以将消化性糊精与难消化性糊精组合使用。此时,优选为糊精类中至少含有80质量%的难消化性糊精,更优选含有90质量%以上。
这些糊精类可以单独地或者将两种以上组合而用作本发明的血中酒精浓度上升抑制剂。本发明的血中酒精浓度上升抑制剂还可以与具有血中酒精浓度上升抑制效果的其他化合物、或者降低血中醛浓度的化合物组合而使用。作为具有血中酒精浓度上升抑制效果的其他化合物,例如可以列举:甘油、肉碱、咖啡因、甘氨酸、麦芽糖醇、乳糖醇等。另外,作为降低血中醛浓度的化合物,可以例示乙醇胺、泛硫乙胺(pantethine)、泛酰巯基乙胺(pantetheine)、牛磺酸等。
本发明的血中酒精浓度上升抑制剂通过在酒精饮料摄取前、摄取中、或者摄取后中的任一时刻进行摄取,可以抑制饮酒后血中酒精浓度的上升,但从效果的观点来看,优选在酒精饮料摄取前或者摄取中进行摄取。
摄取方法没有特别限定,例如以水溶液、片剂、颗粒等形态口服摄取。另外,也可以添加在酒精饮料中摄取。还可以在制造酒精饮料时作为副原料而添加。本发明的酒精浓度上升抑制剂的摄取量的适宜量取决于摄取的酒精饮料中所含的酒精质量。优选为相对于摄取的酒精质量以质量换算计为1/2以上,未达到1/2时效果减弱。
在制造酒精饮料时作为副原料而添加的情况下,优选通过如下方法添加。
例如在制造使用或者未使用麦芽的啤酒风味酒精饮料时进行添加的情况下,是添加在糖化步骤结束后的发酵前液中。另外,在制造烧酒鸡尾酒(sochuhighball)或苏打威士忌(highball)时进行添加的情况下,以水溶液的形式或者以碳酸水的形式添加在作为原酒的烧酒或威士忌中。
[实施例]
通过实施例更详细地说明本发明,但本发明并不限定于这些实施例。另外,只要没有特别声明,则%表示质量%。
实施例1
使用灌胃器,对禁食16小时的7~8周龄的维斯塔尔(Wistar)系雄性大鼠口服投予纯化水(H2O)、40%糊精(TK-16)水溶液或者40%难消化性糊精(Fibersol 2(有时简称为FS2))水溶液和等量的40%乙醇水溶液。溶液的投予量合计设为每1kg体重为6g,在投予前(0分钟)及自投予30分钟后起至240分钟后为止经过一段时间从尾静脉采血,并使用和光纯药工业(股份有限公司)的乙醇测定试剂盒(F-试剂盒)测定血中乙醇浓度。将采集的血液与8倍量的0.33M冰浴冷却过氯酸混合,并进行离心分离,将所得的上清液用于测定。
将各溶液投予240分钟后为止的血中乙醇浓度的演变示于图1。血中乙醇浓度于投予60分钟后显示波峰,于240分钟后几乎消失。FS2投予组与纯化水投予组相比,峰浓度显着受到抑制,从投予30分钟后起至120分钟后为止的浓度也显着较低。另一方面,TK-16投予组的血中乙醇浓度也比纯化水投予组抑制得低,但投予60分钟后为止的上升抑制并不显着。
实施例2
使用灌胃器,对禁食16小时的7~8周龄的韦斯系雄性大鼠口服投予纯化水(H2O)、20%难消化性糊精(FS2)水溶液或者40%难消化性糊精(FS2)水溶液和等量的40%乙醇水溶液。将投予的各溶液的难消化性糊精浓度示于表1。
溶液的投予量合计设为每1kg体重为6g,在投予前(0分钟)及自投予30分钟后起至240分后为止经过一段时间从尾静脉采血,并使用F-试剂盒测定血中乙醇浓度。使采集的血液与8倍量的0.33M冰浴冷却过氯酸混合,并进行离心分离,将所获得的上清液用于测定。
表1
组别 | 难消化性糊精浓度(%) |
纯化水(H2O) | 0 |
20%FS2 | 10 |
40%FS2 | 20 |
将各溶液投予240分钟后为止的血中乙醇浓度的演变示于图2。血中乙醇浓度在投予60分钟后显示出波峰,在240分钟后几乎消失。40%FS2投予组与纯化水投予组相比,峰浓度显着受到抑制,从投予30分钟后起至120分钟后为止的血中乙醇浓度也显着较低。另一方面,20%FS2投予组的血中乙醇浓度到投予30分钟后为止,与纯化水投予组相比显示较低的值,此后与纯化水投予组显示出大致相同的演变。
根据以上结果得知,在投予乙醇摄取量的1/2以上的难消化性糊精的情况下,血中酒精浓度的上升受到抑制,理想的投予量是与乙醇摄取量的等量以上。
Claims (3)
1.一种血中酒精浓度上升抑制剂,其特征在于,其以糊精类作为有效成分。
2.根据权利要求1所述的血中酒精浓度上升抑制剂,其特征在于,所述糊精类是选自消化性糊精及难消化性糊精中的至少一种。
3.一种血中酒精浓度上升抑制方法,其特征在于:在摄取酒精时,相对于摄取1质量份酒精,而摄取0.5质量份以上的消化性糊精和/或难消化性糊精。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011274820A JP2013124243A (ja) | 2011-12-15 | 2011-12-15 | 血中アルコール濃度上昇抑制剤 |
JP2011-274820 | 2011-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103156879A true CN103156879A (zh) | 2013-06-19 |
CN103156879B CN103156879B (zh) | 2017-04-05 |
Family
ID=47355885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210539596.3A Active CN103156879B (zh) | 2011-12-15 | 2012-12-13 | 难消化性糊精作为制备血中酒精浓度上升抑制剂的应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9233122B2 (zh) |
EP (1) | EP2604270B1 (zh) |
JP (1) | JP2013124243A (zh) |
KR (1) | KR101974225B1 (zh) |
CN (1) | CN103156879B (zh) |
ES (1) | ES2665028T3 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109152375A (zh) * | 2016-03-31 | 2019-01-04 | 图蒂食品公司 | 颗粒 |
CN112220032A (zh) * | 2020-09-28 | 2021-01-15 | 王利华 | 有增稠作用组份在制备降低饮酒后形成血醇含量食品的用途和包含该组份的食品 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6822762B2 (ja) * | 2015-11-13 | 2021-01-27 | サッポロビール株式会社 | アルコール飲料、アルコール飲料の製造方法、及びアルコール飲料にアルコール吸収抑制効果を付与する方法 |
MY188896A (en) * | 2016-06-01 | 2022-01-12 | Shaochi Hsin | Methods and compositions for reducing digestive/absorptive rates and ratio of food/drinks or reducing a digestive solution |
JP7283216B2 (ja) * | 2018-05-17 | 2023-05-30 | 大正製薬株式会社 | 経口組成物 |
CN111235124B (zh) * | 2020-01-19 | 2023-04-07 | 云南农业大学 | 珠子参糖基转移酶UGTPjm2及其在制备竹节参皂苷IVa上的应用 |
US12012368B2 (en) | 2022-03-29 | 2024-06-18 | Nissan Chemical Corporation | Cage silicate and method for producing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004326A1 (en) * | 2007-06-29 | 2009-01-01 | Randy Andrews | Beverage Additive and Method of Making the Same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3956511A (en) * | 1972-03-31 | 1976-05-11 | General Foods Corporation | Alcohol-containing dextrin powder |
US4594249A (en) * | 1985-06-14 | 1986-06-10 | 21St Century Marketing, Inc. | Method of altering intoxicating effects of alcohol |
JP3380287B2 (ja) | 1992-04-07 | 2003-02-24 | 麒麟麦酒株式会社 | 血中アルコール濃度上昇阻害飲料 |
JP3533231B2 (ja) | 1993-08-20 | 2004-05-31 | 森下仁丹株式会社 | アルコール吸収抑制剤 |
JPH08277221A (ja) | 1995-04-06 | 1996-10-22 | Itouen:Kk | アルコール吸収抑制剤 |
JP4435882B2 (ja) * | 1998-02-09 | 2010-03-24 | 月桂冠株式会社 | アルコール吸収抑制組成物 |
JP4465077B2 (ja) | 2000-02-15 | 2010-05-19 | 株式会社ヤクルト本社 | アルコール吸収代謝調整剤 |
JP4575588B2 (ja) * | 2000-12-22 | 2010-11-04 | トヨタマ健康食品株式会社 | 悪酔い・二日酔い予防剤 |
JP2005021006A (ja) * | 2003-06-30 | 2005-01-27 | Bc:Kk | アルコールによる影響を短時間で解消する飲食品用材料、飲食品、及び解毒剤 |
KR20050029898A (ko) | 2003-09-24 | 2005-03-29 | 충청북도 | 감식초 분말 함유 기능성 식품 |
US7515240B2 (en) | 2004-10-05 | 2009-04-07 | Au Optronics Corporation | Flat display panel and assembly process or driver components in flat display panel |
DE102004060914A1 (de) * | 2004-12-17 | 2006-07-06 | Bioghurt Biogarde Gmbh & Co. Kg | Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen |
WO2006106704A1 (ja) | 2005-03-31 | 2006-10-12 | Fuji Oil Company, Limited | 血中アルコール代謝改善組成物 |
JP4593393B2 (ja) | 2005-07-19 | 2010-12-08 | 本田技研工業株式会社 | 内燃機関におけるブリーザ室の配置構造 |
JP5188181B2 (ja) | 2005-08-25 | 2013-04-24 | 協和発酵バイオ株式会社 | 血中アルコール濃度上昇抑制用組成物 |
JP2007332277A (ja) * | 2006-06-15 | 2007-12-27 | Matsutani Chem Ind Ltd | 難消化性オリゴ糖含有組成物の製造方法及び飲食品 |
KR20080105510A (ko) | 2007-05-31 | 2008-12-04 | 주식회사 일화 | 숙취 해소용 음료 및 그 제조방법 |
JP2010115124A (ja) | 2008-11-11 | 2010-05-27 | Iwata Kagaku Kogyo Kk | 血中エタノール濃度を減少させるための黒糖醗酵生産物 |
US9186350B2 (en) * | 2011-07-12 | 2015-11-17 | Gdb Patent Holdings, Llc | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication |
-
2011
- 2011-12-15 JP JP2011274820A patent/JP2013124243A/ja active Pending
-
2012
- 2012-12-10 KR KR1020120142593A patent/KR101974225B1/ko active IP Right Grant
- 2012-12-11 US US13/711,225 patent/US9233122B2/en active Active
- 2012-12-13 CN CN201210539596.3A patent/CN103156879B/zh active Active
- 2012-12-13 ES ES12196867.1T patent/ES2665028T3/es active Active
- 2012-12-13 EP EP12196867.1A patent/EP2604270B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004326A1 (en) * | 2007-06-29 | 2009-01-01 | Randy Andrews | Beverage Additive and Method of Making the Same |
Non-Patent Citations (1)
Title |
---|
HARIHARAN SANKARAN等: "Enteral macronutrients abolish high blood alcohol levels in chronic alcoholic rats", 《NUTRITION RESEARCH》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109152375A (zh) * | 2016-03-31 | 2019-01-04 | 图蒂食品公司 | 颗粒 |
CN112220032A (zh) * | 2020-09-28 | 2021-01-15 | 王利华 | 有增稠作用组份在制备降低饮酒后形成血醇含量食品的用途和包含该组份的食品 |
Also Published As
Publication number | Publication date |
---|---|
KR20130069422A (ko) | 2013-06-26 |
US9233122B2 (en) | 2016-01-12 |
EP2604270B1 (en) | 2018-03-21 |
JP2013124243A (ja) | 2013-06-24 |
ES2665028T3 (es) | 2018-04-24 |
KR101974225B1 (ko) | 2019-04-30 |
EP2604270A1 (en) | 2013-06-19 |
US20130157975A1 (en) | 2013-06-20 |
CN103156879B (zh) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103156879B (zh) | 难消化性糊精作为制备血中酒精浓度上升抑制剂的应用 | |
JP6923617B2 (ja) | 発酵麦芽飲料及びその製造方法 | |
JP4854199B2 (ja) | 液化酒粕を再発酵して得られる機能性素材 | |
ES2398216T3 (es) | Método para producir etanol usando almidón sin procesar | |
JP6814734B2 (ja) | ビール様発泡性飲料 | |
JP2008504038A (ja) | 前生物学的調製物 | |
JP2013506405A5 (zh) | ||
JP2006325561A5 (zh) | ||
JP2009263655A (ja) | βグルカン組成物 | |
CN107836723B (zh) | 一种益生元添加剂及其制备方法和应用 | |
EP1864670A1 (en) | Sucrase activity inhibitor, glucoamylase activity inhibitor and food and feed containing the same | |
JP2009124994A (ja) | 分岐糖類の製造方法および飲食品 | |
Passman et al. | Effect of soda consumption on urinary stone risk parameters | |
KR101176631B1 (ko) | 진세노사이드 대사체 함량을 높인 가공 홍삼의 제조 방법 | |
CN103571689A (zh) | 一种玉米格瓦斯饮料粉及其使用方法 | |
JP7217089B2 (ja) | 血糖値上昇抑制剤及びこれを含んでなる経口組成物 | |
JP6648973B2 (ja) | 植物由来β−グルカン含有シロップ | |
JP6046297B2 (ja) | 血中アルコール濃度上昇抑制剤 | |
JP2012135291A (ja) | 酒かす発酵エキスおよびその粉末品とそれらの製造方法 | |
Okoye et al. | Combined effects of aqueous extracts of Tetracarpidium Conophorum (Walnuts) and Vernonia Amygdalina (Bitter leaves) on the pancreas and kidney of alloxan induced diabetic wistar rats | |
JP2016190801A (ja) | 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤 | |
Shunji et al. | Individual differences in blood alcohol concentrations after moderate drinking are mainly regulated by gastric emptying rate together with ethanol distribution volume | |
JPH0217151B2 (zh) | ||
JP2596770B2 (ja) | 風味の豊富な穀類加水分解物 | |
US6558666B1 (en) | Chromium-containing carbohydrase enzyme food supplement composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |